Should you build or buy Cell & Gene Therapy Orchestration?
Cell and gene therapy orchestration software tracks a patient-specific cell or gene therapy from collection through manufacturing to infusion, maintaining chain of identity and chain of custody at every handoff between clinic, courier and manufacturing site. Buyers are pharmaceutical and biotech companies commercializing autologous or allogeneic therapies, along with the networks and logistics providers supporting them.
Buy or use a service-plus-platform model as the starting point, most likely OCELLOS for orchestration, NMDP where center network and cell sourcing matter, or Cryoportal where shipment operations are the gap. Own the operating model and the integrations to your sites, manufacturer and couriers, and extend the platform there rather than building the core. A sponsor-owned layer is justified only for a large developer with a stable global process and validated systems already in place.
Build it, buy it, or bridge?
When building makes sense
A sponsor-owned orchestration layer is justified only when the therapy's delivery model is genuinely the company's own competitive asset, and only a handful of companies have proven they can carry that. Novartis built CellChain to own chain of identity for Kymriah, and its scale and years of investment in a validated global stack are what make that build defensible. That is the exception, not the template. Vineti, once positioned as a platform other developers could adopt to avoid building their own, stopped operating as an independent company, which is direct evidence of how hard it is to sell a general-purpose version of this core rather than build it inside one company's own operation. A mainstream biotech, especially one launching its first commercial cell or gene therapy, does not have the years or the validated infrastructure Novartis brought to its own build, and should not expect to replicate it on a normal commercial timeline.
When buying makes sense
Most developers should start with a service-plus-platform model rather than build. TrakCel's OCELLOS now ships as a pay-as-you-go product with no deployment fee, charging only as patients are enrolled, specifically to remove the upfront cost barrier that early-stage biotechs face; the platform reports more than 4,000 users and more than 350 site deployments globally as of its most recent public figures. That kind of scale and per-patient pricing model is difficult for any single developer to replicate on its own, since the orchestration vendor spreads its validation and integration cost across many sponsors' patients rather than one. Buy the orchestration core, and put your own engineering effort into the integrations that connect it to your specific manufacturing sites, couriers and treatment centers, which is where a developer's own process genuinely differs from a competitor's.
The desk read
Build-versus-buy analysis for Cell & Gene Therapy Orchestration is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.
Frequently asked
Is Novartis's CellChain proof that other companies should build their own orchestration platform?
No. Novartis built CellChain to own chain of identity for Kymriah with years of investment and a validated global infrastructure most developers do not have. It is the strongest evidence that a sponsor-owned build is possible, but also that it takes resources only a handful of companies can commit.
What happened to Vineti, and what does that mean for buyers?
Vineti, once a platform aimed at letting other developers avoid building their own orchestration core, stopped operating as an independent company. That is a caution against betting a therapy's commercial launch on a single vendor's survival, and a reason to evaluate a vendor's own financial stability alongside its feature set.
How has vendor pricing changed for smaller or earlier-stage biotechs?
TrakCel introduced a pay-as-you-go version of its OCELLOS platform specifically to remove upfront deployment fees, charging only as patients are enrolled rather than through an annual subscription or minimum commitment. That model is aimed directly at biotechs that could not previously justify the cost of orchestration software before their first commercial patient.
What should a developer build even when it buys the orchestration core?
The integrations connecting the platform to its own manufacturing sites, couriers and treatment centers, since those reflect a developer's actual operating model rather than a generic workflow. That is where a developer's process genuinely differs from a competitor's, not in the underlying chain-of-identity engine.